Hoffnungsträger

Novo Nordisk’s CagriSema Fails to Meet Goals vs. Eli Lilly’s Tirzepatid – Stock Drops

by

Berlin – Shares in Novo Nordisk experienced a significant downturn on Monday, February 23, 2026, following the release of Phase 3 trial data for its investigational weight-loss drug, CagriSema. The data revealed that CagriSema did not demonstrate superiority to Eli Lilly’s tirzepatide, currently marketed as Mounjaro and Zepbound, in terms of weight loss. This setback … Read more

Vitamin D & MS: Study Shows Promise, But Supplements Often Overdose

by

Vitamin D: A Potential Therapeutic Agent for Multiple Sclerosis, But Supplement Risks Demand Caution The promise of vitamin D as a potential therapeutic intervention for multiple sclerosis (MS) is gaining traction with emerging research, but a parallel rise in concerns regarding the quality and safety of over-the-counter supplements highlights a growing disconnect between targeted medical … Read more